R

Radiopharm Theranostics Ltd
NASDAQ:RADX

Watchlist Manager
Radiopharm Theranostics Ltd
NASDAQ:RADX
Watchlist
Price: 4.96 USD 0.61% Market Closed
Market Cap: $11.6B

ROA

-48.4%
Current
Improving
by 6.7%
vs 3-y average of -55.1%

Return on Assets (ROA) measures how efficiently a company uses its assets to generate profit. It shows how much net income is earned for each dollar of assets.

ROA
-48.4%
=
Net Income
AU$-38.3m
/
Avg Total Assets
AU$79.3m

Return on Assets (ROA) measures how efficiently a company uses its assets to generate profit. It shows how much net income is earned for each dollar of assets.

ROA
-48.4%
=
Net Income
$-38.3m
/
Avg Total Assets
AU$79.3m

Peer Comparison

Country Company Market Cap ROA
AU
Radiopharm Theranostics Ltd
ASX:RAD
64m AUD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
394.7B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
175B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.2B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.6B USD
Loading...
AU
CSL Ltd
ASX:CSL
88.6B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44.1B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.5B USD
Loading...

Market Distribution

Lower than 81% of companies in Australia
Percentile
19th
Based on 4 438 companies
19th percentile
-48.4%
Low
-3 276.3% — -27.2%
Typical Range
-27.2% — 0.8%
High
0.8% — 4 870.2%
Distribution Statistics
Australia
Min -3 276.3%
30th Percentile -27.2%
Median -8.5%
70th Percentile 0.8%
Max 4 870.2%

Radiopharm Theranostics Ltd
Glance View

Market Cap
11.6B USD
Industry
Biotechnology

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-11-25. The firm is a developer of platform of radiopharmaceutical products for both diagnostic and therapeutic uses. The company has a pipeline of four licensed platform technologies, namely Nano- monoclonal antibodies (mAbs) technology, Pivalate, AVb6 Integrin and PSA-mAb. Nano-mAbs technology platform provides Nano-mAbs, which are made using genetically engineered camelid derived single domain antibodies (sdAb), that are labelled with radioisotopes to diagnose and treat specific cancers expressing HER-2, TROP-2, PD-L1 and PTK7 receptors. Pivalate is an F-FPIA radiotracer, and its technology is based on a short chain carbohydrate. Its clinical program includes five Phase I clinical trials, five Phase II clinical trials, and two Phase I clinical trials targeting a various cancer, including breast, lung, kidney, head and neck, pancreatic and brain. Its pipeline consists of RAD101, RAD102, RAD104, RAD105, RAD106, and RAD201 among others.

RADX Intrinsic Value
37.63 USD
Undervaluation 87%
Intrinsic Value
Price
R
What is Return on Assets?
Return on Assets (ROA) measures how efficiently a company uses its assets to generate profit. It shows how much net income is earned for each dollar of assets.
How is ROA calculated?

ROA is calculated by dividing the Net Income by the Avg Total Assets.

ROA
-48.4%
=
Net Income
AU$-38.3m
/
Avg Total Assets
AU$79.3m
What is Radiopharm Theranostics Ltd's current ROA?

The current ROA for Radiopharm Theranostics Ltd is -48.4%, which is above its 3-year median of -55.1%.

How has ROA changed over time?

Over the last 2 years, Radiopharm Theranostics Ltd’s ROA has decreased from -43.7% to -48.4%. During this period, it reached a low of -65.2% on Jun 30, 2024 and a high of -43.7% on May 30, 2023.

Back to Top